We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$5.59B
AUM Growth
+$1.23B
Cap. Flow
+$490M
Cap. Flow %
8.77%
Top 10 Hldgs %
47.55%
Holding
148
New
37
Increased
36
Reduced
28
Closed
32

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$87.6M
2
BURL icon
Burlington
BURL
+$81.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$66.9M
4
HAE icon
Haemonetics
HAE
+$44.2M
5
WSM icon
Williams-Sonoma
WSM
+$43.8M

Top Sells

Rank Stock Value
1
TJX icon
TJX Companies
TJX
+$74.6M
2
LNTH icon
Lantheus
LNTH
+$57.7M
3
AAP icon
Advance Auto Parts
AAP
+$50.2M
4
NKE icon
Nike
NKE
+$42.9M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.15%
2 Miscellaneous 31.91%
3 Consumer Discretionary 10.03%
4 Consumer Staples 7.94%
5 Communication Services 2.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$811B
$1.16B 20.69%
27,000
-1,973,000
-99% -$824M
OEF icon
2
PUT
iShares S&P 100 ETF
OEF
$20.4B
$619M 11.09%
+27,000
New +$5.13M
AVTX icon
3
Avalo Therapeutics
AVTX
$1.07B
$128M 2.29%
13,576
+2,245
+20% +$18.8M
BIIB icon
4
Biogen
BIIB
$31.6B
$127M 2.28%
368,000
+80,000
+28% +$24.2M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$134B
$121M 2.17%
600,000
+208,000
+53% +$43.5M
BMY icon
6
Bristol-Myers Squibb
BMY
$133B
$112M 2.01%
1,678,000
+178,000
+12% +$11.6M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$107M 1.91%
660,000
+124,000
+23% +$19.9M
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.47B
$102M 1.83%
3,324,000
-88,000
-3% -$2.7M
ALKS icon
9
Alkermes
ALKS
$7.77B
$95.6M 1.71%
3,900,000
+376,000
+11% +$8.36M
PTCT icon
10
PTC Therapeutics
PTCT
$5.78B
$88.4M 1.58%
2,092,000
+696,000
+50% +$29.8M
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$395M
$88M 1.58%
2,000,000
+352,000
+21% +$17.2M
IOVA icon
12
Iovance Biotherapeutics
IOVA
$3.95B
$87.7M 1.57%
+3,372,000
New +$87.6M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$83.6B
$87.1M 1.56%
156,000
-19,000
-11% -$9.63M
AMZN icon
14
Amazon
AMZN
$2.77T
$86M 1.54%
500,000
– –
TVTX icon
15
Travere Therapeutics
TVTX
$6.22B
$83.9M 1.5%
5,748,000
+3,392,000
+144% +$66.9M
BURL icon
16
Burlington
BURL
$15.9B
$82.6M 1.48%
+256,462
New +$81.6M
INCY icon
17
Incyte
INCY
$25.5B
$81.1M 1.45%
964,000
-68,000
-7% -$5.67M
ZYME icon
18
Zymeworks
ZYME
$2.05B
$69.4M 1.24%
2,000,000
+350,000
+21% +$11.1M
MDT icon
19
Medtronic
MDT
$119B
$64.1M 1.15%
516,000
-20,000
-4% -$2.51M
CPB icon
20
Campbell Soup
CPB
$6.47B
$59.8M 1.07%
1,312,000
+388,000
+42% +$18.7M
BLUE
21
DELISTED
bluebird bio
BLUE
$58.7M 1.05%
141,739
-9,882
-7% -$3.91M
VNDA icon
22
Vanda Pharmaceuticals
VNDA
$328M
$58.4M 1.05%
2,714,000
-1,082,000
-29% -$19.4M
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$12.4B
$57.7M 1.03%
592,000
+242,000
+69% +$28.6M
CPRX
24
DELISTED
Catalyst Pharmaceutical
CPRX
$57.5M 1.03%
10,000,000
– –
LULU icon
25
lululemon athletica
LULU
$11.3B
$56.9M 1.02%
155,994
+122,621
+367% +$40.4M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Armistice Capital held 148 positions worth $5.59B, up 28% from $4.36B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital deployed $490M of net new capital in Q2 2021, opening 37 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 3,372,000 shares worth $87.7M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 47% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $40.6M trimmed.

  • Armistice Capital's largest Q2 2021 buy was Iovance Biotherapeutics: 3,372,000 shares worth $87.7M.
  • Armistice Capital added most to Travere Therapeutics in Q2 2021, an estimated $66.9M increase.
  • Armistice Capital's biggest Q2 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $40.6M.
  • Armistice Capital fully exited TJX Companies in Q2 2021, selling an estimated $74.6M.
  • Armistice Capital's ten largest holdings make up 48% of its $5.59B portfolio in Q2 2021.
  • Armistice Capital opened 37 new positions and closed 32 in Q2 2021.
  • Armistice Capital's portfolio value rose 28% quarter-over-quarter to $5.59B.

Based on Armistice Capital's 13F filing for Q2 2021, filed 16 Aug 2021.